Adrian was formerly Global Clinical Leader of Early- and Late-Stage Immuno-Oncology/Hematology at Pfizer, New York, where he built a portfolio of studies for Pfizer’s PD-L1 inhibitor Bavencio and immune agonist Utomilumab.
Prior to that he was Global Clinical lead at Bristol-Myers Squibb, responsible for the Early-and Late-Stage development of several small molecule inhibitors, including Dasatinib.
His graduate and post-graduate medical training was at the John Radcliffe Hospital Oxford and Addenbrooke’s Hospital Cambridge, UK. He was elected Charles and Katherine Darwin Research Fellow, at Darwin College, Cambridge.
His work with Nobel Prize winner César Milstein at the MRC Laboratory of Molecular Biology led to the discovery of soluble human CD antigens and a novel method for refolding proteins.